You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Baxter
McKinsey
Moodys
Colorcon

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Patent: 9,980,947

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,980,947
Title:Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: ##STR00001## and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Inventor(s): Labadie; Sharada (Sunnyvale, CA), Liang; Jun (Los Altos Hills, CA), Ortwine; Daniel Fred (San Ramon, CA), Wang; Xiaojing (Foster City, CA), Zbieg; Jason (South San Francisco, CA), Zhang; Birong (Union City, CA), Goodacre; Simon Charles (Harlow, GB), Ray; Nicholas Charles (Harlow, GB), Li; Jun (Foster City, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:14/972,326
Patent Claims:see list of patent claims

Details for Patent 9,980,947

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Dow
McKinsey
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.